Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lipocine ( (LPCN) ) has provided an update.
Lipocine Inc. announced progress in its Phase 3 clinical trial for LPCN 1154, an oral brexanolone formulation for postpartum depression (PPD), with one-third of patients randomized and topline results expected in the second quarter of 2026. The trial, conducted in an outpatient setting, aims to establish LPCN 1154 as a standard of care for PPD, offering rapid relief with a 48-hour dosing schedule and no significant risk to breastfed infants, potentially supporting a 505(b)(2) NDA submission in 2026.
The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s overall stock score is driven by a strong balance sheet and positive corporate developments, which are offset by ongoing profitability challenges and bearish technical indicators. The company’s active pipeline and strategic initiatives offer potential upside, but financial and valuation concerns remain significant.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that uses its proprietary technology platform to develop innovative products with effective oral delivery. The company focuses on creating differentiated, patient-friendly oral delivery options targeting large markets with significant unmet medical needs, including postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis.
Average Trading Volume: 24,937
Technical Sentiment Signal: Sell
Current Market Cap: $15.23M
For a thorough assessment of LPCN stock, go to TipRanks’ Stock Analysis page.